METTL3 and leukemia: Indeed, METTL3, the most well‐described m6A writer associated with carcinogenesis, was found upregulated in leukemia, as well as pancreatic, breast, and lung cancers, whereas in endometrial carcinoma, glioblastoma, and prostate cancer it was reported as downregulated [17].